-
EPI-001 Workflows for AR Signaling Research
2026-09-24
Use EPI-001 to probe androgen receptor signaling beyond the ligand-binding domain, including exploratory AR/ARv7 studies in triple-negative breast cancer. This guide turns published TNBC findings into a practical workflow while separating reported evidence from suggested pilot conditions.
-
PLGA Nano-Adjuvant Boosts Mucosal Immunity in Chicks
2026-09-24
A chick H9N2 vaccination study reports that PEI-modified, PLGA-based nanoparticles co-formulated with Lagenaria siceraria polysaccharide and retinoic acid combine sustained release with intestinal targeting. The formulation was associated with stronger serum IgG and intestinal IgA responses, alongside immune and intestinal changes that suggest a route to coordinating systemic and mucosal immunity.
-
PARP Biology Beyond the Bench: Translational Lessons
2026-09-24
Coronavirus research shows how PARP activity can shape both viral replication and interferon responses, but the effect depends on viral context. This article translates that mechanistic insight into a careful experimental strategy for 3-Aminobenzamide (PARP-IN-1), distinguishing broad pharmacological perturbation from individual PARP functions and outlining practical considerations across antiviral, cardiovascular, and kidney research.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-23
A 2022 Cancers study identified ATRX deficiency as a genotype-linked vulnerability to several multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further support evaluating ATRX status when interpreting RTK inhibitor studies and designing temozolomide-based experimental strategies.
-
ATRX-Deficient Glioma and RTK Inhibitor Sensitivity
2026-09-22
The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its drug-screening and combination-treatment data support evaluating ATRX status when interpreting RTK inhibitor trials and when designing temozolomide-based treatment studies.
-
Poria Cocos, NRF2, and Ferroptosis in ALD
2026-09-22
The reference study identifies a mechanistic link between Poria cocos polysaccharides, NRF2-dependent redox control, and ferroptosis in alcoholic liver disease. By combining animal and cell models with ML385 and ferrostatin-1 interventions, it suggests that oxidative stress and iron handling are actionable components of alcohol-related liver injury.
-
3-Aminobenzamide: PARP Signaling in Translation
2026-09-21
A mechanistic and strategic guide to using 3-Aminobenzamide (PARP-IN-1) to interrogate oxidative stress, vascular dysfunction, diabetic nephropathy, and PARP-linked innate immunity while maintaining translational discipline.
-
Calpain Inhibitor II, ALLM: Assay Logic for FAK
2026-09-21
Calpain Inhibitor II, ALLM enables a time-resolved strategy for separating calpain–FAK proteolysis from downstream apoptosis. This article translates recent TNBC findings into practical protease inhibition assay decisions while preserving the compound’s important calpain–cathepsin selectivity limits.
-
Benzyl Quinolone Carboxylic Acid for M1 Assays
2026-09-20
Benzyl Quinolone Carboxylic Acid (BQCA) enables controlled amplification of acetylcholine responses while preserving the opportunity to measure M1 receptor signaling bias. This guide translates its allosteric pharmacology into practical BRET, cellular signaling, neuronal activity, and Alzheimer’s disease research workflows.
-
MitMAB: A Mechanistic Lens for EV Uptake
2026-09-19
MitMAB provides a focused way to test dynamin-dependent vesicle uptake in physiologically relevant intestinal models. This article connects the compound’s mechanism and handling requirements with polarity-aware milk extracellular vesicle assays, emphasizing causal interpretation rather than simple uptake measurement.
-
FK866 (APO866) Workflows for NAMPT Research
2026-09-19
FK866 (APO866) enables controlled NAD depletion for mechanistic studies spanning hematologic cancer research and vascular-cell senescence. This practical guide connects dose design, metabolic readouts, mitochondrial assays, and troubleshooting to help researchers distinguish target-linked effects from nonspecific toxicity.
-
Coronavirus Macrodomains Counter PARP Antiviral Activity
2026-09-18
Grunewald et al. showed that coronavirus macrodomains protect viral replication by opposing PARP-dependent ADP-ribosylation and its enhancement of interferon responses. Pharmacologic inhibition and targeted depletion identified PARP12 and PARP14 as important host restriction factors, providing a mechanistic framework for studying coronavirus–host interactions.
-
Annexin V-Cy5 Apoptosis Kit: Lab Scenarios
2026-09-17
This scenario-driven guide explains how Annexin V-Cy5 Apoptosis Kit, SKU K2005, supports defensible Annexin V apoptosis detection in microscopy and flow cytometry workflows. It connects phosphatidylserine exposure with practical decisions in microglial stress, lysosomal dysfunction, protocol optimization, data interpretation, and product selection.
-
Phenacetin Workflows for PK and Metabolism Studies
2026-09-17
Phenacetin provides a practical, research-only small-molecule comparator for absorption, metabolism, analytical recovery, and organoid workflows. This guide connects its solvent and stability profile with assay design while showing how to use it responsibly alongside, but not as a substitute for, emerging PDK4 inhibitor studies.
-
Berberine hydrochloride Gut–Bone Workflows
2026-09-17
Berberine hydrochloride supports practical AMPK, microbiome, tuft-cell, barrier, and osteoimmune assay workflows. This guide translates a new gut–bone mechanism into controlled exposure, multi-omics, and troubleshooting strategies while distinguishing research evidence from clinical claims.